SCHEMBL17677939

SCHEMBL17677939

Cc1cnn(-c2ccc(Nc3cc(-c4ccc5cnn(C)c5c4)nc(N4CCOCC4)n3)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PIK3CA P42336 13/20 0.46
▸ PIK3CG P48736 3/20 0.44
▸ PIK3CD O00329 3/20 0.44
▸ PIK3CB P42338 3/20 0.44
▸ MTOR P42345 1/20 0.44
▸ PI4KB Q9UBF8 1/20 0.44
▸ JUN P05412 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ MAPK9 P45984 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17673842 0.90 LMNA (0.59) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673643 0.88 MAPT (0.45) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673620 0.88 MAPT (0.46) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673877 0.87 MAPK10 (0.50) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17677913 0.87 PIK3CA (0.55) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673766 0.87 PIK3CA (0.46) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673778 0.87 PIK3CA (0.48) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17677942 0.86 PIK3CA (0.47) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673786 0.86 PIK3CA (0.49) MAPTLMNAPIK3CAPIK3CGPIK3CD
SCHEMBL17673757 0.86 MAPK8 (0.48) MAPTLMNAPIK3CAPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 — — US disclosed
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 — — US disclosed
WO-2016057834-A9 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2017-04-13 — — WO disclosed
WO-2016057834-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2016-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES HPSE, GAA, MAN2B1 MAPT 3263/4885LMNA 2070/4885PIK3CA 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback